Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

By afschroeder • May 10, 2026

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 May 9. doi: 10.1007/s13555-026-01774-2. Epub ahead of print. PMID: 42105056.

Tags: Dermatology, Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score, Obesity, Olive View DoM, plaque psoriasis, Psoriasis Scalp Severity Index (PSSI), Publications, scalp psoriasis, tildrakizumab

Use of ancillary studies in pediatric spitzoid neoplasms: A retrospective cohort study

Chen A, Krenitsky A, Perry SS, Tan KW, Swick BL, Anderson KR, Barry KK, Kelsey B, Carlberg VM, Coughlin CC, Craddock M, Fadzeyeva H, Ferringer[...]

Ethical Considerations of Omitting Genital Examination During Skin Cancer Screening

Chou P, Lee K, Grant-Kels JM, Farshchian M. Ethical Considerations of Omitting Genital Examination During Skin Cancer Screening. J Am Acad Dermatol. 2026 Apr 28:S0190-9622(26)02571-5.[...]

Practice Patterns and Geographic Distribution of Fellowship-Trained MD-PhD Mohs Surgeons in the United States

Zhou AE, Moon J, Al-Dojaily Y, Kim J, Feng H. Practice Patterns and Geographic Distribution of Fellowship-Trained MD-PhD Mohs Surgeons in the United States. Dermatol[...]